Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 23, 2026, 6:02 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 385–408 of 8,511 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Control Group Clear all
Active, not recruiting Phase 2 Interventional

Study of Olatorepatide in Adult Participants Living With Overweight or Obesity in the US

NCT07431086
View directory record Official record
Conditions
Overweight or Obesity
Interventions
Olatorepatide, Placebo
Drug
Lead sponsor
Regeneron Pharmaceuticals
Industry
Eligibility
18 Years to 65 Years
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026
U.S. locations
3
States / cities
Walnut Creek, California • Winter Park, Florida • San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Jun 17, 2026 · Synced Oct 23, 2026, 6:02 PM EDT
Completed Phase 3 Interventional Results available

A Study to Evaluate Efficacy and Safety of Cabotegravir (CAB) Long Acting (LA) Plus (+) Rilpivirine (RPV) LA Versus BIKTARVY® (BIK) in Participants With Human Immunodeficiency Virus (HIV)-1 Who Are Virologically Suppressed

NCT04542070
View directory record Official record
Conditions
HIV Infections
Interventions
Cabotegravir Tablets, Cabotegravir Injectable Suspension (CAB LA), Rilpivirine Tablets, Rilpivirine Injectable Suspension (RPV LA), BIKTARVY Tablets (BIK)
Drug
Lead sponsor
ViiV Healthcare
Industry
Eligibility
18 Years and older
Enrollment
687 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
41
States / cities
Bakersfield, California • Beverly Hills, California • Los Angeles, California + 32 more
Source: ClinicalTrials.gov public record
Updated Jun 4, 2024 · Synced Oct 23, 2026, 6:02 PM EDT
Terminated Phase 2 Interventional Results available

Study of Apremilast to Evaluate the Safety and Effectiveness for Patients With Rheumatoid Arthritis

NCT01285310
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
Apremilast 30 mg, Apremilast 20 mg, Placebo
Drug
Lead sponsor
Amgen
Industry
Eligibility
18 Years and older
Enrollment
237 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
29
States / cities
Gilbert, Arizona • Phoenix, Arizona • La Mesa, California + 23 more
Source: ClinicalTrials.gov public record
Updated May 8, 2020 · Synced Oct 23, 2026, 6:02 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers

The Effect of Tablet Size on Cognitive Performance Caffeine

NCT03694886
View directory record Official record
Conditions
Placebo Effect
Interventions
Caffeine Anhydrous with small sucrose pill, Placebo - large sucrose pill, Caffeine Anhydrous with large sucrose pill, Placebo - small sucrose pill
Drug · Other
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years to 40 Years
Enrollment
120 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2019
U.S. locations
1
States / cities
Denver, Colorado
Source: ClinicalTrials.gov public record
Updated Apr 17, 2019 · Synced Oct 23, 2026, 6:02 PM EDT
Completed Phase 3 Interventional Results available

Migraine Study in Adolescent Patients

NCT00843024
View directory record Official record
Conditions
Migraine Disorders
Interventions
Sumatriptan and Naproxen Sodium, Placebo
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
12 Years to 17 Years
Enrollment
589 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
79
States / cities
Gilbert, Arizona • Litchfield Park, Arizona • Phoenix, Arizona + 71 more
Source: ClinicalTrials.gov public record
Updated Jan 18, 2017 · Synced Oct 23, 2026, 6:02 PM EDT
Recruiting Phase 2 Interventional

Control Systems Engineering for Weight Loss Maintenance

NCT06244888
View directory record Official record
Conditions
Overweight and Obesity
Interventions
Intervention Targeting Stress and Emotion Regulation, Intervention Targeting Motivation and Self-efficacy for Weight Management, Intervention for Normalization of Eating, Intervention Targeting Physical Activity and Sleep
Behavioral
Lead sponsor
The Miriam Hospital
Other
Eligibility
18 Years to 70 Years
Enrollment
180 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
1
States / cities
Providence, Rhode Island
Source: ClinicalTrials.gov public record
Updated Apr 2, 2024 · Synced Oct 23, 2026, 6:02 PM EDT
Completed Not applicable Interventional

Pilot Study to Determine Efficacy of Cyclamen Europaeum Extract Nasal Spray in Patients With Acute Sinusitis

NCT00552773
View directory record Official record
Conditions
ACUTE SINUSITIS
Interventions
Cyclamen Europaeum
Drug
Lead sponsor
Dey
Industry
Eligibility
18 Years to 70 Years
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
25
States / cities
Birmingham, Alabama • Oxford, Alabama • Jonesboro, Arkansas + 19 more
Source: ClinicalTrials.gov public record
Updated Jun 4, 2013 · Synced Oct 23, 2026, 6:02 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Testing the Efficacy of a Spousal Support Enhanced Weight Loss Program on Weight Loss Among African American Men

NCT02458053
View directory record Official record
Conditions
Overweight, Weight Loss, Obese
Interventions
Attends with partner, Couples Skill Training, Face to face group sessions, Self Monitor, Notebook, Feedback
Behavioral · Other
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
18 Years to 65 Years · Male only
Enrollment
104 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2017
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Sep 14, 2017 · Synced Oct 23, 2026, 6:02 PM EDT
Active, not recruiting Phase 3 Interventional

A Study to Evaluate the Safety, Tolerability, and Efficacy of BIIB017 (Peginterferon Beta-1a) in Pediatric Participants for the Treatment of Relapsing-Remitting Multiple Sclerosis

NCT03958877
View directory record Official record
Conditions
Multiple Sclerosis, Relapsing-Remitting
Interventions
BIIB017 (peginterferon beta-1a), Interferon beta type 1a
Drug
Lead sponsor
Biogen
Industry
Eligibility
10 Years to 18 Years
Enrollment
152 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2027
U.S. locations
3
States / cities
La Jolla, California • Chapel Hill, North Carolina • Norfolk, Virginia
Source: ClinicalTrials.gov public record
Updated Sep 24, 2026 · Synced Oct 23, 2026, 6:02 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Virtual Reality on Efficacy of Donning and Doffing PPE

NCT04937257
View directory record Official record
Conditions
Medical Training
Interventions
Virtual Reality, E-module
Other
Lead sponsor
Montefiore Medical Center
Other
Eligibility
Not listed
Enrollment
54 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2021
U.S. locations
1
States / cities
The Bronx, New York
Source: ClinicalTrials.gov public record
Updated Jun 24, 2021 · Synced Oct 23, 2026, 6:02 PM EDT
Active, not recruiting Phase 3 Interventional

A Study to Evaluate the Effectiveness and Safety of Dysport® for the Prevention of Episodic Migraine in Adults

NCT06047457
View directory record Official record
Conditions
Episodic Migraine
Interventions
Botulinum toxin type A, Placebo
Biological · Other
Lead sponsor
Ipsen
Industry
Eligibility
18 Years and older
Enrollment
751 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
66
States / cities
Birmingham, Alabama • Phoenix, Arizona • Scottsdale, Arizona + 58 more
Source: ClinicalTrials.gov public record
Updated Sep 4, 2026 · Synced Oct 23, 2026, 6:02 PM EDT
Active, not recruiting Not applicable Interventional Accepts healthy volunteers

Concurrent Vestibular Activation and Postural Training Using Virtual Reality

NCT05942781
View directory record Official record
Conditions
Vestibular Disorder
Interventions
Vestibular training using VR followed by Control, Control followed by Vestibular training using VR
Device
Lead sponsor
Clarkson University
Other
Eligibility
55 Years to 80 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2025
U.S. locations
1
States / cities
Potsdam, New York
Source: ClinicalTrials.gov public record
Updated Jun 18, 2025 · Synced Oct 23, 2026, 6:02 PM EDT
Completed Phase 4 Interventional Results available

Study to Evaluate the Effect of Omalizumab on Improving the Tolerability of Specific Immunotherapy in Patients With Persistent Allergic Asthma

NCT00267202
View directory record Official record
Conditions
Allergic Asthma
Interventions
Placebo, Omalizumab, Immunotherapy
Drug
Lead sponsor
Novartis
Industry
Eligibility
18 Years to 55 Years
Enrollment
275 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2008
U.S. locations
1
States / cities
East Hanover, New Jersey
Source: ClinicalTrials.gov public record
Updated Sep 14, 2016 · Synced Oct 23, 2026, 6:02 PM EDT
Completed No phase listed Observational

Detection, Education, Research and Decolonization Without Isolation in Long-term Care Facilities

NCT01302210
View directory record Official record
Conditions
Methicillin Resistant Staphylococcus Aureus
Interventions
Decolonization
Drug
Lead sponsor
Endeavor Health
Other
Eligibility
18 Years and older
Enrollment
22,302 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
1
States / cities
Evanston, Illinois
Source: ClinicalTrials.gov public record
Updated Sep 11, 2019 · Synced Oct 23, 2026, 6:02 PM EDT
Completed Phase 2 Interventional Results available

An Efficacy and Safety Study to Compare Three Doses of BEA 2180 BR to Tiotropium and Placebo in the Respimat Inhaler.

NCT00528996
View directory record Official record
Conditions
Pulmonary Disease, Chronic Obstructive
Interventions
BEA 2180 BR, Tiotropium Bromide, Placebo
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
40 Years to 100 Years
Enrollment
2,080 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
56
States / cities
Jasper, Alabama • Mobile, Alabama • Berkeley, California + 50 more
Source: ClinicalTrials.gov public record
Updated Aug 24, 2021 · Synced Oct 23, 2026, 6:02 PM EDT
Completed Phase 4 Interventional Results available

Comparing Local Anesthetics for TAP Block During Abdominally-based Free Flap for Breast Reconstruction

NCT03700970
View directory record Official record
Conditions
Breast Reconstruction, Anesthesia, Transverse Abdominis Plane Block
Interventions
Liposomal bupivacaine, Regular bupivacaine
Drug
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
18 Years to 85 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Jan 24, 2022 · Synced Oct 23, 2026, 6:02 PM EDT
Completed Phase 3 Interventional

Study Evaluating Bifeprunox in Bipolar Depression

NCT00245973
View directory record Official record
Conditions
Depression Bipolar
Interventions
Bifeprunox
Drug
Lead sponsor
Wyeth is now a wholly owned subsidiary of Pfizer
Industry
Eligibility
18 Years to 65 Years
Enrollment
380 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
40
States / cities
Birmingham, Alabama • Beverly Hills, California • National City, California + 36 more
Source: ClinicalTrials.gov public record
Updated Dec 5, 2007 · Synced Oct 23, 2026, 6:02 PM EDT
Completed Phase 2 Interventional

12-Week Study in Adult Subjects With Asthma

NCT01516073
View directory record Official record
Conditions
Asthma
Interventions
Fluticasone Propionate
Drug
Lead sponsor
Dey
Industry
Eligibility
18 Years to 60 Years
Enrollment
629 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
1
States / cities
Greenville, South Carolina
Source: ClinicalTrials.gov public record
Updated Dec 11, 2014 · Synced Oct 23, 2026, 6:02 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

The Impact of Integrating an Internet Weight Control Program Into Primary Care

NCT01606813
View directory record Official record
Conditions
Overweight, Obese
Interventions
Usual Care, Brief Physician Counseling, Referral and access to an internet weight control program, Brief follow up email notes from PCPs
Other · Behavioral
Lead sponsor
Milton S. Hershey Medical Center
Other
Eligibility
21 Years to 70 Years
Enrollment
611 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2016
U.S. locations
1
States / cities
Hershey, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Dec 8, 2016 · Synced Oct 23, 2026, 6:02 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Paleolithic Diets vs T2D and Improvements in the Metabolic Syndrome

NCT00548782
View directory record Official record
Conditions
Type 2 Diabetes Mellitus
Interventions
Paleolithic diet, ADA ( American Diabetes Association) recommended diet
Other
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years and older
Enrollment
22 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2016
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Feb 28, 2020 · Synced Oct 23, 2026, 6:02 PM EDT
Completed Phase 3 Interventional

Study to Assess the Safety and Efficacy of NRP104 in Adults With Attention-Deficit Hyperactivity Disorder (ADHD)

NCT00334880
View directory record Official record
Conditions
Attention Deficit Hyperactivity Disorder, Attention Deficit Disorders With Hyperactivity, Attention Deficit Hyperactivity Disorders
Interventions
NRP104
Drug
Lead sponsor
New River Pharmaceuticals
Industry
Eligibility
18 Years to 55 Years
Enrollment
420 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006
U.S. locations
48
States / cities
Little Rock, Arkansas • El Centro, California • Irvine, California + 43 more
Source: ClinicalTrials.gov public record
Updated Jul 2, 2009 · Synced Oct 23, 2026, 6:02 PM EDT
Completed Phase 4 Interventional

An Open-label Trial of Metformin for Weight Control of Pediatric Patients on Antipsychotic Medications.

NCT00391261
View directory record Official record
Conditions
Schizophrenia, Schizoaffective Disorder, Schizophreniform Disorder, Bipolar Disorder, Autism Spectrum Disorders
Interventions
Metformin
Drug
Lead sponsor
Cambridge Health Alliance
Other
Eligibility
10 Years to 18 Years
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
1
States / cities
Medford, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 25, 2010 · Synced Oct 23, 2026, 6:02 PM EDT
Completed No phase listed Observational

Effectiveness of Entresto (Sacubitril/Valsartan) in Japanese Patients With Hypertension

NCT06604897
View directory record Official record
Conditions
Essential Hypertension
Interventions
Not listed
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
20 Years to 99 Years
Enrollment
1,405 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
1
States / cities
East Hanover, New Jersey
Source: ClinicalTrials.gov public record
Updated Aug 14, 2026 · Synced Oct 23, 2026, 6:02 PM EDT
Not listed Phase 2 Interventional

Improving Blood Glucose Control With a Computerized Decision Support Tool: Phase 2

NCT00654797
View directory record Official record
Conditions
Critically Ill, Hyperglycemia
Interventions
glucose control with computer generated recommendations
Procedure
Lead sponsor
Intermountain Health Care, Inc.
Other
Eligibility
1 Month and older
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2018
U.S. locations
10
States / cities
Madera, California • Saint Paul, Minnesota • Lebanon, New Hampshire + 5 more
Source: ClinicalTrials.gov public record
Updated Feb 26, 2015 · Synced Oct 23, 2026, 6:02 PM EDT